INNOVATIVE TECHNOLOGY COULD TRANSFORM WOMEN’S HEALTH ACROSS EUROPE
Tirat Carmel, Israel, April, 22, 2010 –The ExAblate® 2000, a magnetic resonance guided focus ultrasound system, received special recognition by being included in the 10th nationwide Girls´ Day in Germany. This event held on April 21st, 2010 at the German Federal Chancellery, celebrates innovation, science and technology and encourages school girls to consider science as a career. Chancellor Merkel accompanied by a group of 24 schoolgirls visited the booth of Techniker Krankenkasse (TK), a prominent German health insurance company, observed a demonstration of the ExAblate system at work and heard an explanation by Dr. Matthias Matzko of the Amper Kliniken AG in Dachau.
Each year hundreds of thousands of women across Europe are diagnosed with uterine fibroids and until now, many have had to resort to hysterectomies to alleviate the symptoms of this often devastating condition.
“This technology has the potential to improve the health care of thousands of women across Europe. It is important that women with uterine fibroids now have a choice of a non-invasive treatment and furthermore may be able to protect their future fertility”, said Dr. Matthias Matzko of the Amper Kliniken AG in Dachau. The Amper Kliniken is one of four treatment centers in Germany that offer this innovative technology to women. The clinic worked with Techniker Krankenkasse (TK) to become the first German health insurance offering reimbursement for this new technique for the treatment of uterine fibroids. The ExAblate treatment is administered at more than 30 leading hospitals across Europe.
“TK wants to advance reasonable and promising medical innovations, so that our contract patients with uterine fibroids may already benefit from this gentle treatment. Patients do not need to wait for years until this procedure will be integrated in the basic coverage.” explained Mr. Lütjohann, the head of the myoma project treatment at TK.
“Amper Kliniken provides a great example of what can be achieved when a treatment center works with the healthcare provider looking for ways to improve patient care” said Dr. Kobi Vortman, President and Chief Executive Officer of InSightec.
The ExAblate system destroys non-invasively the fibroids using high intensity focused ultrasound waves to ablate the fibroids. The surrounding tissue is spared, and the level of adverse events is very low compared to other treatment alternatives.
ExAblate has CE and FDA approval for the treatment of Uterine Fibroids and a CE approval for the treatment of bone metastases. MRgFUS technology is being investigated in such areas as bone metastases, breast, liver, brain and prostate cancer in clinical trials sponsored by InSightec around the world.